
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS

Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
Fecha de publicación: 2 abril de 2020 Development and Evaluation of a Set of Spike and Receptor Binding Domain‐Based...
The dialyzable leukocyte extract TransferonTM inhibits tumor growth and brain metastasis in a murine model of prostate cancer. VER...
Regulatory Pathway for Licensing Biotherapeutics in Mexico. VER MÁS
Fecha de publicación: 28 de agosto de 2022 Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies Ver más
Fecha de publicación: 10 de abril de 2019 CD80 Expression Correlates with IL-6 Production in THP-1-Like Macrophages Costimulated with...
Determination of Peptide Profile Consistency and Safety of Collagen Hydrolysates as Quality Attributes. VER MÁS
Phage Display Libraries for Antibody Therapeutic Discovery and Development. VER MÁS
Fecha de publicación: 20 de marzo del 2021 Consistency of a dialyzable leucocyte extract manufactured at GMPfacilities by Nuclear...

+52 (55) 5729 6000 Ext. 62543
Escuela Nacional de Ciencias Biológicas. Prolongación de Carpio y Plan de Ayala S/N, Del. Miguel Hidalgo, CDMX, C.P. 11340.
©2026 UDIBI